Description
Summary Abstract
MA-2TZ is a synthetic, acylated peptide that functions as a potent dual co-agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It belongs to the incretin-based polyagonist class of investigational peptides, designed to harness the complementary metabolic effects of GIP and GLP-1 receptor activation simultaneously. MA-2TZ incorporates a long-chain fatty acid side chain conjugated via a linker to an amino acid position in the peptide backbone, enabling reversible albumin binding that extends circulating half-life to support once-weekly dosing intervals. Research has demonstrated that dual GIP/GLP-1 co-agonism produces greater reductions in body weight, HbA1c, and adipose tissue mass than GLP-1 receptor agonism alone, attributable to the complementary actions of GIP on adipose tissue lipid handling, bone metabolism, and central appetite regulation.
Clinical Indications
The dual incretin receptor co-agonist mechanism of MA-2TZ supports investigation across several metabolic research contexts:
- Type 2 diabetes and glycemic control: Concurrent GIPR and GLP-1R activation augments glucose-dependent insulin secretion from pancreatic β-cells and suppresses α-cell glucagon release, producing superior fasting and postprandial glucose lowering compared to single-receptor agonism.
- Obesity and adipose tissue remodeling: GIP receptor activation on adipocytes modulates lipid uptake, lipolysis, and adipogenesis in a complementary manner to GLP-1–driven appetite suppression and gastric emptying delay, yielding additive reductions in adipose mass in preclinical and clinical models.
- Metabolic-associated steatotic liver disease (MASLD): Combined GIPR/GLP-1R agonism suppresses hepatic de novo lipogenesis, reduces visceral fat flux to the liver, and attenuates hepatic inflammation, making MA-2TZ a relevant tool in steatohepatitis research models.
Contraindications
- Pancreatic cell studies: The insulin secretagogue effect is strictly glucose-dependent; co-incubation with compounds that disrupt glucose sensing in β-cell models may confound outcome interpretation.
- GI motility models: As with GLP-1 class peptides, dual incretin co-agonism delays gastric emptying; experimental designs measuring GI transit require appropriate controls for this effect, though tachyphylaxis to motility effects may develop with sustained exposure.
- Thyroid C-cell studies: GLP-1 receptor activation has been associated with thyroid C-cell hyperplasia in rodent models; this species-specific effect should be considered in murine thyroid research designs.
Mechanism of Action (MOA)
MA-2TZ exploits the complementary biology of two incretin receptor systems through a single, co-agonist peptide scaffold:
GLP-1 Receptor Agonism
MA-2TZ activates the GLP-1 receptor (GLP-1R), a class B G-protein–coupled receptor expressed on pancreatic β-cells, hypothalamic appetite centers, the gastrointestinal tract, and the cardiovascular system. GLP-1R signaling via Gsα–cAMP–PKA cascades enhances glucose-stimulated insulin secretion, suppresses glucagon, delays gastric emptying, and centrally reduces appetite and food intake.
GIP Receptor Co-Agonism
Concurrent GIPR activation provides complementary metabolic effects: GIP potentiates β-cell insulin secretion in synergy with GLP-1; in adipose tissue, GIPR signaling regulates lipid uptake and adipogenesis via cAMP-mediated lipolytic regulation. The combination overcomes the reduced GIP efficacy observed in individuals with type 2 diabetes through receptor-level synergy.
Albumin-Mediated Half-Life Extension
MA-2TZ carries a long-chain unsaturated fatty diacid (C-20 type) conjugated via a linker to the peptide backbone, enabling reversible serum albumin binding. This pharmacokinetic engineering strategy reduces renal filtration and proteolytic degradation, extending the circulating half-life to approximately one week and supporting once-weekly dosing in research settings.
Hepatic and Lipid Metabolic Effects
At the hepatic level, the dual incretin co-agonism suppresses de novo lipogenesis gene expression, reduces VLDL-triglyceride production, and attenuates macrophage-mediated hepatic inflammation. In adipose tissue, GIP-driven modulation of lipid handling improves peripheral insulin sensitivity by reducing circulating non-esterified fatty acid (NEFA) flux to the liver.
Key Features & Specifications
MA-2TZ provides a pharmacologically advanced dual-incretin research peptide with an engineered pharmacokinetic profile:
Chemical Analysis
| Property | Specification Reference Data |
|---|---|
| Class | Acylated incretin-mimetic peptide; dual GIP/GLP-1 receptor co-agonist |
| Internal Code | MA-2TZ |
| Lipid Modification | Long-chain unsaturated fatty diacid (C-20 type) conjugated via linker for albumin binding |
| Half-Life | Approximately 7 days (once-weekly dosing profile) |
| Route | Subcutaneous injection (lyophilized, reconstituted) |
| Form / Variation | 5 MG Lyo — P-027 ($51.00) / 10 MG Lyo — P-044 ($81.00) / 20 MG Lyo — P-015 ($139.00) / 40 MG Lyo — P-082 ($249.00) |
Storage, Safety, and Handling
Storage Protocol
Store lyophilized MA-2TZ at −20 °C in sealed vials, protected from light and moisture, until use. Reconstitute with bacteriostatic water or sterile saline immediately before use; reconstituted solutions should be stored at 2–8 °C and used within 28 days. Avoid repeated freeze-thaw cycles of reconstituted peptide.
Handling & Compliance
Handle using aseptic technique; use appropriate PPE including gloves, eye protection, and a biosafety cabinet for reconstitution of injectable preparations. Researchers should adhere to institutional peptide hormone handling protocols. Subcutaneous injection research requires IACUC or equivalent ethics committee approval for animal studies.